Featured Publications
Making diabetes technology accessible to all
Nally L, Sherr J. Making diabetes technology accessible to all. Nature Medicine 2024, 30: 1832-1833. PMID: 38918631, DOI: 10.1038/s41591-024-03082-8.Peer-Reviewed Original ResearchImpact of school‐supervised ultra‐long‐acting basal insulin injections on ketosis in youth with T1D and elevated haemoglobin A1c: A pilot study
Nally L, Sherr J, Tichy E, Weyman K, Urban A, Shabanova V, McCollum S, Steffen A, Tamborlane W, Van Name M. Impact of school‐supervised ultra‐long‐acting basal insulin injections on ketosis in youth with T1D and elevated haemoglobin A1c: A pilot study. Diabetic Medicine 2023, 40: e15123. PMID: 37078999, PMCID: PMC10524154, DOI: 10.1111/dme.15123.Peer-Reviewed Original ResearchConceptsBasal insulin injectionsDiabetic ketoacidosisPercent of participantsBlood β-hydroxybutyrateInsulin injectionsBasal insulin dosesBasal insulin typeType 1 diabetesManagement of youthDegludec groupSignificant ketosisAcute complicationsBasal insulinInsulin dosesRisk of ketosisInjected insulinHigher hemoglobinInsulin administrationElevated hemoglobinInsulin typeKetone levelsHigh riskSchool nursesDegludecLarger sample size
2024
Shifting the paradigm of type 1 diabetes: a narrative review of disease modifying therapies
O’Donovan A, Gorelik S, Nally L. Shifting the paradigm of type 1 diabetes: a narrative review of disease modifying therapies. Frontiers In Endocrinology 2024, 15: 1477101. PMID: 39568817, PMCID: PMC11576206, DOI: 10.3389/fendo.2024.1477101.Peer-Reviewed Original ResearchDisease modifying therapiesStages of T1DFood and Drug AdministrationType 1 diabetesLong-term insulin dependenceDestruction of pancreatic beta cellsModifying therapiesDiagnosis of type 1 diabetesClinical diagnosis of T1DClinical diseasePathogenesis of T1DDetection of autoantibodiesDiagnosis of T1DNarrative reviewSymptoms of hyperglycemiaPancreatic beta cellsMechanism of actionAutoimmune conditionsInsulin-dependentPublished trialsGlycemic changesDrug AdministrationInsulin deficiencyTherapyClinical diagnosisIntegrated Strategies to Support Diabetes Technology in Pregnancy
Nally L, Blanchette J. Integrated Strategies to Support Diabetes Technology in Pregnancy. Obstetrics And Gynecology 2024, 144: 599-607. PMID: 39208437, PMCID: PMC11486578, DOI: 10.1097/aog.0000000000005710.Peer-Reviewed Original ResearchDiabetes technologyImprove diabetes careQuality of lifeImprove glycemic outcomesDiabetes careBenefits of continuous glucose monitoringManaging diabetesPregnant individualsAutomated insulin delivery systemsConstant diligenceGlycemic outcomesWell-beingType 1 diabetesPregnancyDiabetesContinuous glucose monitoringGlucose monitoringRegulatory approval
2023
Personalized Digital Health Information to Substantiate Human-Delivered Exercise Support for Adults With Type 1 Diabetes
Ash G, Nally L, Stults-Kolehmainen M, De Los Santos M, Jeon S, Brandt C, Gulanski B, Spanakis E, Baker J, Weinzimer S, Fucito L. Personalized Digital Health Information to Substantiate Human-Delivered Exercise Support for Adults With Type 1 Diabetes. Clinical Journal Of Sport Medicine 2023, 33: 512-520. PMID: 36715983, PMCID: PMC10898917, DOI: 10.1097/jsm.0000000000001078.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringExercise supportHealth informationDigital health informationBody mass indexType 1 diabetesCommunity-based sampleSevere hypoglycemiaMass indexPsychosocial assessmentCGM useHigh satisfaction ratingsPhysician oversightType 1Future interventionsGlucose monitoringMedical readinessMolecular biomarkersBaseline observationsInterventionSatisfaction ratingsAdultsExerciseBehavioral skillsSingle group
2022
Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes
Deshpande S, Weinzimer SA, Gibbons K, Nally LM, Weyman K, Carria L, Zgorski M, Laffel LM, Doyle FJ, Dassau E. Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes. Journal Of Diabetes Science And Technology 2022, 18: 363-371. PMID: 35971681, PMCID: PMC10973844, DOI: 10.1177/19322968221116384.Peer-Reviewed Original ResearchType 1 diabetesUnannounced exercisePercent timeGlucose standard deviationParents/guardiansSecondary outcomesAdverse eventsPrimary outcomeBlood glucose dataPump therapyPreliminary safetyAutomated Insulin DeliveryContinuous glucose monitoring dataPediatric participantsGlucose monitoring dataAge-based cohortsArtificial pancreas systemsLarge mealsInsulin deliveryGlucose dataYoung childrenDiabetesYounger cohortsChildrenCohort1025-P: Racial Disparities in Diabetes Distress and Technology Use in Adolescents with Type 1 Diabetes
WILCOX A, MENCHER S, NALLY L, WEINZIMER S. 1025-P: Racial Disparities in Diabetes Distress and Technology Use in Adolescents with Type 1 Diabetes. Diabetes 2022, 71 DOI: 10.2337/db22-1025-p.Peer-Reviewed Original ResearchNon-Hispanic whitesDiabetes distressAdverse short-term outcomesBurden of diabetesShort-term outcomesType 1 diabetesHigher HbA1cContinuous glucose monitorElevated hemoglobinHigh prevalenceHigh riskDiabetesREM groupEthnic groupsEthnic disparitiesInsulin pumpAdolescent SurveyType 1Group of adolescentsRacial disparitiesSpeakers bureauDiabetes technologyNovo NordiskGlucose monitorAdditional mediators
2021
Plasmapheresis as an Early Treatment for Severe Hypertriglyceridemia, Acute Pancreatitis, and Diabetic Ketoacidosis
Kravetz AM, Sanghavi P, Bhargava V, Shi RZ, Nally LM. Plasmapheresis as an Early Treatment for Severe Hypertriglyceridemia, Acute Pancreatitis, and Diabetic Ketoacidosis. AACE Clinical Case Reports 2021, 7: 315-319. PMID: 34522772, PMCID: PMC8426612, DOI: 10.1016/j.aace.2021.03.009.Peer-Reviewed Original ResearchDiabetic ketoacidosisType 1 diabetesAcute pancreatitisSevere hypertriglyceridemiaNew-onset type 1 diabetesZinc transporter 8 autoantibodiesGlutamic acid decarboxylase 65Islet cell antigen 512Hospital day 5Courses of plasmapheresisType 2 diabetesCourse of treatmentPancreatitis symptomsLifestyle modificationCutaneous xanthomasHospital admissionSerious complicationsClinical statusInsulin deficiencyIntravenous fluidsInsulin infusionLipemia retinalisEarly treatmentEarly initiationEffective treatmentThe Influence of Health Mindset on Perceptions of Illness and Behaviors Among Adolescents
John-Henderson NA, Wright RC, Manke KJ, Fotuhi O, Zuckerman B, Nally L, Mueller CM. The Influence of Health Mindset on Perceptions of Illness and Behaviors Among Adolescents. International Journal Of Behavioral Medicine 2021, 28: 727-736. PMID: 33721232, DOI: 10.1007/s12529-021-09972-2.Peer-Reviewed Original ResearchConceptsHealthy adolescentsHealth behaviorsHealth mindsetsType 1 diabetesImplications of illnessPerception of illnessMethodsIn study 1Chronic conditionsAdditional diseaseJudgments of illnessChronic illnessHealth perceptionOverall healthIllnessGlucose monitoringAdolescentsGreater frequencyYoung adolescentsStudy 2Study 1DiabetesInjuryDiseaseAdjunctive Therapies for Type 1 Diabetes
Nally L, Van Name M, Tamborlane W, Sherr J. Adjunctive Therapies for Type 1 Diabetes. Contemporary Endocrinology 2021, 143-150. DOI: 10.1007/978-3-030-64133-7_13.Chapters
2020
A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention
Nally LM, Wagner J, Sherr J, Tichy E, Weyman K, Ginley MK, Zajac K, Desousa M, Shabanova V, Petry NM, Tamborlane WV, Van Name M. A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention. Endocrine Practice 2020, 27: 545-551. PMID: 34120699, PMCID: PMC8206518, DOI: 10.1016/j.eprac.2020.11.017.Peer-Reviewed Original Research
2019
Pharmacologic treatment options for type 1 diabetes: what’s new?
Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV. Pharmacologic treatment options for type 1 diabetes: what’s new? Expert Review Of Clinical Pharmacology 2019, 12: 471-479. PMID: 30892094, PMCID: PMC6488361, DOI: 10.1080/17512433.2019.1597705.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdjunctive therapyType 1 diabetesInsulin analoguesMimic physiologic insulin secretionGLP-1 receptor agonistsPhysiologic insulin secretionPharmacologic treatment optionsDPP-4 inhibitorsType 2 diabetesVariety of insulinBiosynthetic human insulinPotential adverse effectsSGLT1/2 inhibitorsBasal insulinPharmacologic treatmentTreatment optionsReceptor agonistInsulin secretionSGLT-2Abnormal physiologyProlonged durationTherapyDiabetesInsulinNovel drugs
2015
Gene therapy with neurogenin3, betacellulin and SOCS1 reverses diabetes in NOD mice
Li R, Buras E, Lee J, Liu R, Liu V, Espiritu C, Ozer K, Thompson B, Nally L, Yuan G, Oka K, Chang B, Samson S, Yechoor V, Chan L. Gene therapy with neurogenin3, betacellulin and SOCS1 reverses diabetes in NOD mice. Gene Therapy 2015, 22: 876-882. PMID: 26172077, PMCID: PMC4636470, DOI: 10.1038/gt.2015.62.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAnimalsBasic Helix-Loop-Helix Transcription FactorsBetacellulinDiabetes Mellitus, ExperimentalFemaleGenetic TherapyImmunosuppression TherapyInsulinIslets of LangerhansIslets of Langerhans TransplantationLiverMiceMice, Inbred NODNerve Tissue ProteinsSuppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling ProteinsConceptsSuppressor of cytokine signaling 1NOD miceGene therapyModel of autoimmune diabetesDiabetic miceLineage-defining transcription factorsGlucose-stimulated insulin secretionHelper-dependent adenovirusActivated T cellsLong-term reversal of diabetesRat insulin promoterReversal of diabetesShortage of donor isletsIslet neogenesisOverexpression suppressorIslet growth factorsNeo-isletsType 1 diabetesCytokine signaling 1Transcription factorsTransfer diabetesNon-obeseTreated mice liverAutoimmune diabetesT cells